Intracellular organisms

International Journal of Antimicrobial Agents

Volumn 9, Issue 1, 1997, Pages 61-70

  Maurin, M ^a   Raoult, Didier ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Intracellular organisms; Phagocytes; Rickettsiae

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; CHLORAMPHENICOL; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; JOSAMYCIN; MACROLIDE; OFLOXACIN; PEFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; ROXITHROMYCIN; TETRACYCLINE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BARTONELLA HENSELAE; CAT SCRATCH DISEASE; CELLULAR DISTRIBUTION; CHLAMYDIACEAE; DRUG PENETRATION; EUKARYOTIC CELL; HEMANGIOMATOSIS; HUMAN; INFECTION; MICROORGANISM; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; REVIEW; RICKETTSIA; RICKETTSIOSIS; TRACHOMA;

EID: 0030876041     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(97)00028-9     Document Type: Article

References (93)

1. Moulder JW. Comparative biology of intracellular parasitism. Microbiol Rev 1985;49:239-337.
2. Holmes BH, Quie PG, Windhorst DB, Pollara B, Good RA. Protection of phagocytized bacteria from the killing action of antibiotics. Nature 1966;210:1131-3.
3. Mandell GL. Interaction of intraleukocytic bacteria and antibiotics. J Clin Invest 1973;52:1673-9.
4. Mandell GL, Vest TK. Killing of intraleukocytic Staphylococcus aureus by rifampin: in vitro and in vivo studies. J Infect Dis 1972;125:486-90.
5. Hackstadt T, Williams JC. Biochemical stratagem for obligate parasitism of eukaryotic cells by Coxiella burnetii. Proc Natl Acad Sci USA 1981;78:3240-4.
6. Mukkada AJ, Meade JC, Glaser TA, Bonventre PF. Enhanced metabolism of Leishmania donovani amastigotes at acid pH: an adaptation for intracellular growth. Science 1985;229:1099-2001.
7. Lam C, Mathison GE. Effect of low intraphagolysosomal pH on antimicrobial activity of antibiotics against ingested staphylococci. J Med Microbiol 1983;16:309-16.
8. Maurin M, Benoliel AM, Bongrand P, Raoult D. Phagolysosomal alkalinization an the bactericidal effect of antibiotics: the Coxiella burnetii paradigm. J Infect Dis 1992;166:1097-102.
9. Maurin M, Raoult D. Phagolysosomal alkalinization and intracellular killing of Staphylococcus aureus by amikacin. J Infect Dis 1994;169:330-6.
10. Drancourt M, Raoult D. Methodology of antibiotics testing for intracellular pathogens. In: Raoult D, editor. Antimicrobial Agents and Intracellular Pathogens. 5th ed. Boca Raton: CRC Press, 1993:71-85.
11. Cooksey RC, Crawford JT, Jacobs WR, et al. A rapid method for screening antimicrobial agents for activities against a strain of Mycobacterium tuberculosis expressing firefly luciferase. Antimicrob Agents Chemother 1993;37:1348-52.
12. Uchida T. Rickettsia japonica, the etiologic agent of oriental spotted fever. Microbiol Immunol 1993;37:91-102.
13. Stewart RS. Flinders Island spotted fever: a newly recognised endemic focus of tick typhus in Bass Strait, Part 1. Clinical and epidemiological features. Med J Australia 1991;154:94-9.
14. Baird RW, Lloyd M, Stenos J, Ross BC, Stewart RS, Dwyer B. Characterization and comparison of Australian human spotted fever group rickettsiae. J Clin Microbiol 1992;30:2896-902.
15. Tarasevich IV, Makarova V, Fetisova NF, Stepanov A, Mistkarova E, Balayeva N, et al. Astrakhan fever: new spotted fever group rickettsiosis. Lancet 1991;337:172-3.
16. Kelly PJ, Beati L, Mason PR, Matthewman LA, Roux V, Raoult D. Rickettsia africae sp nov, the etiological agent of African tick bite fever. Int J Syst Bact 1996;46:611-4.
17. Schriefer ME, Sacci JBJ, Dumler JS, Bullen MG, Azad AF. Identification of a novel rickettsial infection in a patient diagnosed with murine typhus. J Clin Microbiol 1994;32:949-54.
18. Raoult D, Brouqui P, Roux V. A new spotted-fever-group Rickettsiosis. Lancet 1996;348:412.
19. Yu X, Fan M, Xu G, Liu Q, Raoult D. Genotypic and antigenic identification of two new strains of spotted fever group Rickettsiae isolated from China. J Clin Microbiol 1993;31:83-8.
20. Raoult D, Walker DH. Rickettsia rickettsii and other spotted fever group rickettsiae. In: Mandell GL, Gordon RJ, Bennett JE, editors. Principles and Practice of Infectious Diseases, 3rd edn. New York: Churchill Livingstone, 1990:1465-9.
21. Bella-Cueto F, Font-Creus B, Segura-Porta F, Espejo-Arenas E, Lopez-Parez P, Munoz-Espin T. Comparative, randomized trial of one-day doxycycline versus 10-day tetracycline therapy for Mediterranean spotted fever. J Infect Dis 1987;155:1056-8.
22. Huys J, Freyens P, Kayihigi J, Van den Berghe G. Treatment of epidemic typhus. A comparative study of chloramphenicol, trimethoprim-sulfamethoxazole and doxycycline. Trans Roy Soc Trop Med Hyg 1973;67:718-21.
23. Brown GW, Saunders JP, Singh S, Huxsoll DL, Shirai A. Single dose doxycycline therapy for scrub typhus. Trans Roy Soc Trop Med Hyg 1978;72:412-6.
24. Huys J, Kayhigi J, Freyens P, Berghe GV. Single-dose treatment of epidemic typhus with doxycyline. Chemotherapy 1973;18:314-7.
25. Krause DW, Perine PL, McDade JE, Awoke S. Treatment of louse-borne typhus fever with chloramphenicol, tetracycline or doxycycline. East Afr Med J 1975;52:421-7.
26. Perine PL, Krause DW, Awoke S, McDade JE. Single-dose doxycycline treatment of louse-borne relapsing fever and epidemic typhus. Lancet 1974;2:742-4.
27. Gudiol F, Pallares R, Carratala J, Bolao F, Ariza J, Rufi G, et al. Randomized double-blind evaluation of ciprofloxacin and doxycycline for Mediterranean spotted fever. Antimicrob Agents Chemother 1989;33:987-8.
28. Raoult D, Gallais H, de Micco P, Casanova P. Ciprofloxacin therapy for Mediterranean spotted fever. Antimicrob Agents Chemother 1986;30:606-7.
29. Di Lascio G, Salvini S, Cermola S, Grasso C. Use of pefloxacin in boutonneuse fever. Clin Ther 1991;136:101.
30. Bernard E, Carles M, Politano S, Laffont C, Dellamonica P. Rickettsiosis caused by Rickettsia conorii: treatment by ofloxacin. Rev Infect Dis 1989;11 (Suppl. 5):989.
31. Ruiz-Beltran R, Herrero-Herrero JI. New quinolones in the treatment of Mediterranean Spotted Fever (MSF): a comparative study with other antibiotic regimens. In: Kazar J, Raoult D, editors. Rickettsiae and Rickettsial Diseases. Bratislava: Publishing House of the Slovak Academy of Sciences, 1990:714-7.
32. Eaton M, Cohen MT, Shlim DR, Innes B. Ciprofloxacin treatment of typhus. J Amer Med Assoc 1989;262:772-3.
33. Strand O, Stromberg A. Ciprofloxacin treatment of murine Typhus. Scand J Infect Dis 1990;22:503-4.
34. Mc Clain JB, Joshi B, Rice R. Chloramphenicol, gentamicin, and ciprofloxacin against murine scrub typhus. Antimicrob Agents Chemother 1988;32:285-6.
35. Bella F, Espejo E, Uriz S, Serrano JA, Alegre MD, Tort J. Randomized trial of five-day rifampin versus one-day doxycycline therapy for mediterranean spotted fever. J Infect Dis 1991;164:433-4.
36. Raoult D. Antimicrobial Agents and Intracellular Pathogens. Boca Raton: CRC Press, 1993.
37. Drancourt M, Raoult D. In vitro susceptibilities of Rickettsia rickettsii and Rickettsia conorii to roxithromycin and pristinamycin. Antimicrob Agents Chemother 1989;33:2146-8.
38. Maurin M, Raoult D. In vitro susceptibilities of spotted fever group rickettsiae and Coxiella burnetii to clarithromycin. Antimicrob Agents Chemother 1993;37:2633-7.
39. Powell OW, Kennedy KP, Mc Iver M, Silverstone H. Tetracycline in the treatment of Q fever. Aust Ann Med 1962;11:184-5.
40. Spelman DW. Q fever: a study of 111 consecutive cases. Med J Australia 1982;1:547-50.
41. Perez-del-Molino A, Aguado JM, Riancho JA, Sarnpredo I, Matorras P, Gonzales-Macias J. Erythromycin and the treatment of Coxiella burnetii pneumonia. J Antimicrob Chemother 1991;28:455-9.
42. Raoult D, Torres H, Drancourt M. Shell-vial assay: Evaluation of a new technique for determining antibiotic susceptibility, tested in 13 isolates of Coxiella burnetii. Antimicrob Agents Chemother 1991;35:2070-7.
43. Levy PY, Drancourt M, Etienne J, Auvergnat JC, Beytout J, Sainty JM, et al. Comparison of different antibiotic regimens for therapy of 32 cases of Q fever endocarditis. Antimicrob Agents Chemother 1991;35:533-7.
44. Raoult D, Drancourt M, Vestris G. Bactericidal effect of doxycycline associated with lysosomotropic agents on Coxiella burnetii in P388D1 cells. Antimicrob Agents Chemother 1990;34:1512-4.
45. Dawson JE, Anderson BE, Fishbein DB, Sanchez JL, Goldsmith CS, Wilson KH, et al. Isolation and characterization of an Ehrlichia sp. from a patient diagnosed with human Ehrlichiosis. J Clin Microbiol 1991;29:2741-5.
46. Rikihisa Y. The tribe Ehrlichia and Ehrlichial diseases. Clin Microbiol Rev 1991;4:286-308.
47. Dumler JS, Brouqui P, Aronson J, Taylor JP, Walker DH. Identification of Ehrlichia in human tissue. N Engl J Med 1991;325:1109-10.
48. Brouqui P, Raoult D. In vitro antibiotic susceptibility of the newly recognized agent of human ehrlichiosis: Ehrlichia chaffeensis. Antimicrob Agents Chemother 1992;36:2799-803.
49. Centers for Disease Control and Prevention. Recommendations for the prevention and management of Chlamydia trachomatis infections. Morbid Mortal Wkly Rep 1993;42:1-39.
50. Magat AH, Alger LS, Nagey DA, et al. Double-blind randomized study comparing amoxicillin and erythromycin for the treatment of Chlamydia trachomatis in pregnancy. Obstet Gynecol 1993;81:745-9.
51. Centers for Disease Control and Prevention. 1989 Sexually transmitted diseases treatment guidelines. Morbid Mortal Wkly Rep 1989;38 (Suppl. 8):1-43.
52. Toomey KE, Barnes RC. Treatment of Chlamydia trachomatis genital infection. Rev Infect Dis 1990;12 (Suppl. 6):645-55.
53. Crombleholme WR, Schachter J, Grossman M, et al. Amoxicillin therapy for Chlamydia trachomatis in pregnancy. Obstet Gynecol 1990;75:752-6.
54. Weber JT, Johnson RE. New treatments for Chlamydia trachomatis genital infection. Clin Infect Dis 1995;20 (Suppl. 1):66-71.
55. Martin DH, Mroczkowski TF, Dalu ZA, et al. A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. N Engl J Med 1992;327:921-5.
56. Centers for Disease Control. Psittacosis surveillance. Annual summary 1975-1984. Atlanta: Centers for Disease Control, 1987.
57. Schachter J. Chlamydia psittaci-"reemergence" of a forgotten pathogen. N Engl J Med 1986;315:189-91.
58. Grayston JT. Chlamydia pneumonias. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. 4th ed. New York: Churchill Livingstone, 1995:1696-701.
59. Carithers HA. Cat-scratch disease. An overview based on a study of 1200 patients. Am J Dis Child 1985;139:1124-33.
60. English CK, Wear DJ, Margileth AM, Lissner CR, Walsh GP. Cat scratch disease: isolation and culture of the bacterial agent. J Amer Med Assoc 1988;259:1347-52.
61. Regnery RL, Olson TG, Perkins BA, Bibb W. Serological response to Rochalimaea henselae antigen in suspected catscratch disease. Lancet 1992;339:1443-5.
62. Maurin M, Lepocher H, Mallet D, Raoult D. Antibiotics susceptibility of Afipia felis in axenic medium and in cells. Antimicrob Agents Chemother 1993:37:1410-3.
63. Maurin M, Gasquet S., Ducco C, Raoult D. Minimal inhibitory concentrations of 28 antibiotic compounds to 14 Bartonella (formerly Rochalimaea) isolates. Antimicrob Agents Chemother 1995;39:2387-91.
64. Musso D, Drancourt M, Raoult D. Lack of bactericidal effect of antibiotics except aminoglycosides on Bartonella (Rochalimaea) henselae. J Antimicrob Chemother 1995;36:101-8.
65. Fagan WA, Skinner SM, Ondo A, Williams JT, Anthony K, De Villez RL, et al. Bacillary angiomatosis of the skin and bone marrow in a patient with HIV infection. J Am Acad Dermatol 1995;32:510-2.
66. Koehler JE, Cederberg L. Intra-abdominal mass associated with gastrointestinal hemorrhage: A new manifestation of bacillary angiomatosis. Gastroenterology 1995;109:2011-4.
67. Milam MW, Balerdi JF, Toney JF, Foulis PR, Milam CP. Epithelioid angiomatosis secondary to disseminated cat scratch disease involving the bone marrow and skin in a patient with acquired immune deficiency syndrome: a case report. Amer J Med 1990;88:180-3.
68. Stoler MH, Bonfiglio TA, Staigbigel MT, Pereira M. An atypical subcutaneous infection associated with acquired immune deficiency syndrome. Am J Clin Pathol 1983;80:714-8.
69. Prokesch RC, Hand WL. Antibiotic entry into human polymorphonuclear leukocytes. Antimicrob Agents Chemother 1982;21:373-80.
70. Johnson JD, Hand WL, Francis JB, King-Thompson N, Corwin RW. Antibiotic uptake by alveolar macrophages. J Lab Clin Med 1980;95:429-39.
71. Vaudaux P, Waldvogel FA. Gentamicin antibacterial activity in the presence of human polymorphonuclear leukocytes. Antimicrob Agents Chemother 1979;16:743-9.
72. Forsgren A, Bellahsene A. Antibiotic accumulation in human polymorphonuclears and lymphocytes. Scand J Infect Dis 1985;44:16-23.
73. Hand WL, King-Thompson NL. Contrasts between phagocyte antibiotic uptake and subsequent intracellular bactericidal activity. Antimicrob Agents Chemother 1986;29:135-40.
74. Park JK, Dow RC. The uptake and localization of tetracycline in human blood cells. Br J Exp Pathol 1970;51:179.
75. Brown KN, Percival A. Penetration of antimicrobials into tissue culture cells and leukocytes. Scand J Infect Dis 1978;14:251-60.
76. Hand WL, Boozer RM, King-Thompson WL. Antibiotic uptake by alveolar macrophages of smokers. Antimicrob Agents Chemother 1985;27:42-5.
77. Ekzemplyarov ON. Penetration of tetracycline and streptomycin into macrophages cultured in vitro. Antibiotiki 1965;10:312.
78. Easmon CSF, Crane JP. Comparative uptake of rifampin and rifapentine (DL 473) by human neutrophils. J Antimicrob Chemother 1984;13:585-91.
79. Climax J, Lenehan TJ, Lambe R, Kenny M, Caffrey E, Darragh A. Interaction of animicrobial agents with human peripheral blood leukocytes: uptake and intracellular localization of certain sulfonamides and trimethoprim. J Antimicrob Chemother 1986;17:489-98.
80. Easmon CSF, Crane JP. Cellular uptake of clindamycin and lincomycin. Br J Exp Pathol 1984;65:725-30.
81. Klempner MS, Styrt B. Clindamycin uptake by human neutrophils. J Infect Dis 1981;144:472-9.
82. Carlier MB, Zenebergh A, Tulkens PM. Cellular uptake and subcellular distribution of roxithromycin and erythromycin in phagocytic cells. J Antimicrob Chemother 1987;20 (Suppl.):47-56.
83. Hand WL, King-Thompson NL. Membrane transport of clindamycin in alveolar macrophages. Antimicrob Agents Chemother 1982;21:241-7.
84. Ishiguro M, Koga H, Kohno S, et al. Penetration of macrolides into human polymorphonuclear leukocytes. J Antimicrob Chemother 1989;24:719-30.
85. Gemmell CG. Macrolides and host defenses to respiratory tract pathogens. J Hosp Infect 1991;19 (Suppl. A):11-9.
86. Gladue RP, Bright GM, Isaacson ME, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62,993) in phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989;33:277-82.
87. Anderson R, Joone G, van Rensburg CEJ. An in vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031) a new macrolide antimicrobial agent. J Antimicrob Chemother 1988; 12:923-33.
88. Carlier MB, Scorneaux B, Zeneberg A, Desnottes JF, Tulkens PM. Cellular uptake localization and activity of fluoroquinolones in uninfected and infected macrophages. J Antimicrob Chemother 1990;26:27-39.
89. Pascual A, Garcia I, Perea EJ. Fluorometric measurement of ofloxacin uptake by human polymorphonuclear leukocytes. Antimicrob Agents Chemother 1989;33:653-6.
90. Perea EJ, Garcia I, Pascual A. Comparative penetration of lomefloxacin and other quinolones into human phagocytes. Amer J Med 1992;92 (Suppl 4A):48-51.
91. Pascual A, Garcia I, Conejo MC, et al. Fluorometric and high-performance liquid Chromatographic measurement of quinolone uptake by human neutrophils. Eur J Clin Microbiol Infect D 1991;10:969-71.
92. Easmon CSF, Crane JP. Uptake of ciprofloxacin by human neutrophils. J Antimicrob Chemother 1985;16:67-73.
93. Garcia I, Pascual A, Guzman MC, Perea EJ. Uptake and intracellular activity of sparfloxacin in human polymorphonuclear leukocytes and tissue culture cells. Antimicrob Agents Chemother 1992;36:1053-1056.